|
EP1158985B1
(en)
|
1999-01-13 |
2011-12-28 |
Bayer HealthCare LLC |
OMEGA-CARBOXY ARYL SUBSTITUTED DIPHENYL UREAS AS p38 KINASE INHIBITORS
|
|
ME00275B
(me)
|
1999-01-13 |
2011-02-10 |
Bayer Corp |
ω-KARBOKSIARIL SUPSTITUISANI DIFENIL KARBAMIDI KAO INHIBITORI RAF KINAZE
|
|
US8124630B2
(en)
|
1999-01-13 |
2012-02-28 |
Bayer Healthcare Llc |
ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
|
|
WO2003068229A1
(en)
|
2002-02-11 |
2003-08-21 |
Bayer Pharmaceuticals Corporation |
Pyridine, quinoline, and isoquinoline n-oxides as kinase inhibitors
|
|
SI1478358T1
(sl)
|
2002-02-11 |
2013-09-30 |
Bayer Healthcare Llc |
Sorafenib tozilat za zdravljenje bolezni, značilnih po abnormalni angiogenezi
|
|
WO2003082272A1
(en)
*
|
2002-03-29 |
2003-10-09 |
Chiron Corporation |
Substituted benzazoles and use thereof as raf kinase inhibitors
|
|
US7557129B2
(en)
|
2003-02-28 |
2009-07-07 |
Bayer Healthcare Llc |
Cyanopyridine derivatives useful in the treatment of cancer and other disorders
|
|
CA2526285A1
(en)
|
2003-05-15 |
2004-12-23 |
Arqule, Inc. |
Inhibitors of p38 and methods of using the same
|
|
EP1636585B2
(en)
|
2003-05-20 |
2012-06-13 |
Bayer HealthCare LLC |
Diaryl ureas with kinase inhibiting activity
|
|
EP1663978B1
(en)
|
2003-07-23 |
2007-11-28 |
Bayer Pharmaceuticals Corporation |
Fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions
|
|
KR20060118472A
(ko)
*
|
2003-10-16 |
2006-11-23 |
카이론 코포레이션 |
치환 벤자졸 및 ｒａｆ 키나아제의 저해제로서 그것의 사용
|
|
WO2006010082A1
(en)
*
|
2004-07-08 |
2006-01-26 |
Arqule, Inc. |
1,4-disubstituted naphtalenes as inhibitors of p38 map kinase
|
|
EP2258704A1
(en)
*
|
2004-10-19 |
2010-12-08 |
ArQule, Inc. |
Synthesis of imidazooxazole and imidazothiazole inhibitors of p38 map kinase
|
|
US7429608B2
(en)
*
|
2005-01-20 |
2008-09-30 |
Amgen Inc. |
Benzo[d]imidazol analogs as vanilloid receptor ligands and their use in treatments
|
|
TWI370820B
(en)
*
|
2005-04-27 |
2012-08-21 |
Takeda Pharmaceutical |
Fused heterocyclic compounds
|
|
TWI387592B
(zh)
*
|
2005-08-30 |
2013-03-01 |
Novartis Ag |
經取代之苯并咪唑及其作為與腫瘤形成相關激酶之抑制劑之方法
|
|
WO2007047397A2
(en)
*
|
2005-10-13 |
2007-04-26 |
Smithkline Beecham Corporation |
Phenol ethers as modulators of the opioid receptors
|
|
CN101379060B
(zh)
*
|
2006-02-10 |
2012-05-23 |
转化技术制药公司 |
作为Aurora激酶抑制剂的苯并唑系衍生物、组合物和使用方法
|
|
CA2649288C
(en)
|
2006-04-19 |
2015-11-24 |
Novartis Ag |
6-o-substituted benzoxazole and benzothiazole compounds and methods of inhibiting csf-1r signaling
|
|
PT2046292E
(pt)
|
2006-07-21 |
2010-04-26 |
Novartis Ag |
Formulações de éteres benzimidazolil-piridílicos
|
|
PE20130814A1
(es)
|
2006-08-30 |
2013-08-08 |
Novartis Ag |
Sales de benzimidazolil piridil eteres y formulaciones que las contienen
|
|
JP5294419B2
(ja)
*
|
2007-04-05 |
2013-09-18 |
第一三共株式会社 |
縮合二環式ヘテロアリール誘導体
|
|
CL2008001626A1
(es)
|
2007-06-05 |
2009-06-05 |
Takeda Pharmaceuticals Co |
Compuestos derivados de heterociclos fusionados, agente farmaceutico que los comprende y su uso en la profilaxis y tratamiento del cancer.
|
|
EP2181987B9
(en)
|
2007-08-23 |
2014-09-03 |
Takeda Pharmaceutical Company Limited |
2-Carbonylaminobenzothiazoles and their use for the prophylaxis and treatment of cancer
|
|
JP5350247B2
(ja)
*
|
2007-08-29 |
2013-11-27 |
武田薬品工業株式会社 |
複素環化合物およびその用途
|
|
EP2573087A1
(en)
|
2007-09-21 |
2013-03-27 |
Array Biopharma, Inc. |
Pyridin-2-yl-amino-1,2,4-thiadiazole derivatives as glucokinase activators for the treatment of diabetes mellitus
|
|
BRPI0818003A2
(pt)
*
|
2007-10-18 |
2019-09-24 |
Novartis Ag |
inibidores de csf-1r, composições e métodos de uso
|
|
US8697874B2
(en)
*
|
2008-12-01 |
2014-04-15 |
Takeda Pharmaceutical Company Limited |
Heterocyclic compound and use thereof
|
|
JO3101B1
(ar)
|
2008-12-02 |
2017-09-20 |
Takeda Pharmaceuticals Co |
مشتقات بنزوثيازول كعوامل مضادة للسرطان
|
|
EP2361254A1
(en)
*
|
2008-12-05 |
2011-08-31 |
ArQule, Inc. |
Raf inhibitors and their uses
|
|
CA2754446A1
(en)
|
2009-03-05 |
2010-09-10 |
Daiichi Sankyo Company, Limited |
Pyridine derivative
|
|
WO2011156755A2
(en)
|
2010-06-11 |
2011-12-15 |
Smith & Nephew, Inc. |
Patient-matched instruments
|
|
JP2013531687A
(ja)
|
2010-07-16 |
2013-08-08 |
パーデュー、ファーマ、リミテッド、パートナーシップ |
ナトリウムチャネル遮断剤としてのピリジン化合物
|
|
AU2011303597A1
(en)
|
2010-09-17 |
2013-04-11 |
Purdue Pharma L.P. |
Pyridine compounds and the uses thereof
|
|
CN102276482A
(zh)
*
|
2011-04-11 |
2011-12-14 |
常州大学 |
2-甲氧基-5-溴苯胺的制备方法
|
|
US9408885B2
(en)
|
2011-12-01 |
2016-08-09 |
Vib Vzw |
Combinations of therapeutic agents for treating melanoma
|
|
WO2013136170A1
(en)
|
2012-03-16 |
2013-09-19 |
Purdue Pharma L.P. |
Substituted pyridines as sodium channel blockers
|
|
EP2935257B1
(en)
|
2012-12-20 |
2018-02-07 |
Purdue Pharma LP |
Cyclic sulfonamides as sodium channel blockers
|
|
US9242969B2
(en)
|
2013-03-14 |
2016-01-26 |
Novartis Ag |
Biaryl amide compounds as kinase inhibitors
|
|
CN103435554A
(zh)
*
|
2013-09-06 |
2013-12-11 |
中国药科大学 |
2-苯氨基苯并咪唑类化合物及其用途
|
|
WO2015041534A1
(en)
|
2013-09-20 |
2015-03-26 |
Stichting Het Nederlands Kanker Instituut |
P90rsk in combination with raf/erk/mek
|
|
US9629851B2
(en)
|
2013-09-20 |
2017-04-25 |
Stitching Het Nederlands Kanker Institut—Antoni Van Leeuwenhoek Ziekenhuis |
ROCK in combination with MAPK pathway
|
|
US10730866B2
(en)
|
2014-04-07 |
2020-08-04 |
Purdue Pharma L.P. |
Indole derivatives and use thereof
|
|
WO2015156674A2
(en)
|
2014-04-10 |
2015-10-15 |
Stichting Het Nederlands Kanker Instituut |
Method for treating cancer
|
|
WO2015178770A1
(en)
|
2014-05-19 |
2015-11-26 |
Stichting Het Nederlands Kanker Instituut |
Compositions for cancer treatment
|
|
UY36294A
(es)
|
2014-09-12 |
2016-04-29 |
Novartis Ag |
Compuestos y composiciones como inhibidores de quinasa
|
|
EP3623371A1
(en)
|
2014-12-16 |
2020-03-18 |
Axovant Sciences GmbH |
Geminal substituted quinuclidine amide compounds as agonists of alpha-7 nicotinic acetylcholine receptors
|
|
CN105949178B
(zh)
*
|
2015-03-09 |
2020-05-26 |
西格莱(苏州)生物医药有限公司 |
一种苯并咪唑类化合物、其制备方法、中间体及应用
|
|
CN107847494A
(zh)
|
2015-06-10 |
2018-03-27 |
阿考温特科学股份有限公司 |
作为α7‑烟碱乙酰胆碱受体激动剂的氨基苯并异噁唑化合物
|
|
JP2018523707A
(ja)
|
2015-08-12 |
2018-08-23 |
アクソバント サイエンシズ ゲーエムベーハー |
α７−ニコチン性アセチルコリン受容体のアゴニストとしてのジェミナル置換アミノベンゾイソオキサゾール化合物
|
|
KR101770310B1
(ko)
|
2015-08-24 |
2017-08-24 |
이화여자대학교 산학협력단 |
2-(페닐아미노)벤조[d]옥사졸-5-올 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 염증성 질환의 예방 또는 치료용 약학적 조성물
|
|
EP3383852A4
(en)
*
|
2015-11-30 |
2019-08-28 |
Children's Medical Center Corporation |
COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISEASES
|
|
AU2017329090B9
(en)
|
2016-09-19 |
2019-09-05 |
Novartis Ag |
Therapeutic combinations comprising a RAF inhibitor and a ERK inhibitor
|
|
CN106674264A
(zh)
*
|
2016-12-20 |
2017-05-17 |
苏州汉德创宏生化科技有限公司 |
(2,2,2‑三氟乙氧基)苯硼酸类化合物的合成方法
|
|
WO2018146253A1
(en)
|
2017-02-10 |
2018-08-16 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for the treatment of cancers associated with activation of the mapk pathway
|
|
US11242332B2
(en)
|
2017-03-15 |
2022-02-08 |
Sumitomo Dainippon Pharma Co., Ltd. |
Method for producing benzimidazole derivative
|
|
CA3057969A1
(en)
|
2017-05-02 |
2018-11-08 |
Novartis Ag |
Combination therapy
|
|
EP3652165B1
(en)
*
|
2017-07-12 |
2021-08-25 |
Bristol-Myers Squibb Company |
Five membered-aminoheterocyclic and 5,6-or 6,6-membered bicyclic aminoheterocyclic inhibitors of rock for the treatment of heart failure
|
|
EP3700904B1
(en)
|
2017-10-24 |
2023-07-19 |
Bayer AG |
4h-pyrrolo[3,2-c]pyridin-4-one derivatives
|
|
WO2019133810A1
(en)
|
2017-12-28 |
2019-07-04 |
Tract Pharmaceuticals, Inc. |
Stem cell culture systems for columnar epithelial stem cells, and uses related thereto
|
|
US11447469B2
(en)
*
|
2018-02-07 |
2022-09-20 |
Korea Research Institute Of Chemical Technology |
Hetero ring-fused phenyl compounds for inhibiting TNIK and medical uses thereof
|
|
JP2022500385A
(ja)
|
2018-09-10 |
2022-01-04 |
ミラティ セラピューティクス， インコーポレイテッド |
組み合わせ療法
|
|
EP3877371A4
(en)
|
2018-11-07 |
2022-07-27 |
Dana-Farber Cancer Institute, Inc. |
IMIDAZOPYRIDINE DERIVATIVES AND AZA-IMIDAZOPYRIDINE DERIVATIVES AS JANUS KINASE 2 INHIBITORS AND USES THEREOF
|
|
US12522583B2
(en)
|
2018-11-07 |
2026-01-13 |
Dana-Farber Cancer Institute, Inc. |
Benzimidazole derivatives and aza-benzimidazole derivatives as Janus kinase 2 inhibitors and uses thereof
|
|
EP3876939A4
(en)
|
2018-11-07 |
2022-08-10 |
Dana-Farber Cancer Institute, Inc. |
Benzothiazole derivatives and 7-aza-benzothiazole derivatives as janus kinase 2 inhibitors and uses thereof
|
|
DK3959211T3
(da)
|
2019-04-24 |
2026-04-27 |
Bayer Ag |
4h-pyrrol[3,2-c]pyridin-4-on-forbindelser
|
|
US20240307362A1
(en)
|
2019-04-24 |
2024-09-19 |
Bayer Aktiengesellschaft |
4H-PYRROLO[3,2-c]PYRIDIN-4-ONE COMPOUNDS
|
|
US12403135B2
(en)
|
2019-04-24 |
2025-09-02 |
Bayer Aktiengesellschaft |
4H-pyrrolo[3,2-c]pyridin-4-one derivatives
|
|
EP3969449B1
(en)
|
2019-05-13 |
2025-02-12 |
Novartis AG |
New crystalline forms of n-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methvlphenyl)-2(trifluoromethyl)isonicotinamide as raf inhibitors for the treatment of cancer
|
|
EP4126861B1
(en)
|
2020-03-31 |
2025-06-18 |
Bayer Aktiengesellschaft |
3-(anilino)-2-[3-(3-alkoxy-pyridin-4-yl]-1,5,6,7-tetrahydro-4h-pyrrolo[3,2-c]pyridin-4-one derivatives as egfr inhibitors for the treatment of cancer
|
|
US11691963B2
(en)
|
2020-05-06 |
2023-07-04 |
Ajax Therapeutics, Inc. |
6-heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors
|
|
US20240051970A1
(en)
*
|
2020-12-16 |
2024-02-15 |
Ifm Due, Inc. |
Compounds and compositions for treating conditions associated with sting activity
|
|
US12043632B2
(en)
|
2020-12-23 |
2024-07-23 |
Ajax Therapeutics, Inc. |
6-heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors
|
|
WO2023009708A1
(en)
*
|
2021-07-29 |
2023-02-02 |
Ajax Therapeutics, Inc. |
Heteroaryloxy triazolo- and imidazo-azines as jak2 inhibitors
|
|
WO2023086319A1
(en)
|
2021-11-09 |
2023-05-19 |
Ajax Therapeutics, Inc. |
6-he tero aryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors
|
|
US12162881B2
(en)
|
2021-11-09 |
2024-12-10 |
Ajax Therapeutics, Inc. |
Forms and compositions of inhibitors of JAK2
|